Unknown

Dataset Information

The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries.


ABSTRACT:

Purpose

The aim of this study is to investigate the role of health-related quality-of-life (QoL) data in relative effectiveness assessments (REAs) of new anti-cancer drugs across European jurisdictions, during health technology assessment procedures.

Methods

Comparative analysis of guidelines and publicly available REAs in six European jurisdictions of anti-cancer drugs approved by EMA between 2011 and 2013.

Results

Fourteen anti-cancer drugs were included, adding up to 79 REAs. Whilst all guidelines state that QoL is a relevant endpoint to determine the relative effectiveness of new cancer drugs, QoL data were included in only 54% of the 79 reports and their impact on the recommendations was limited.

Conclusions

Whilst national guidelines recognize the relevan

SUBMITTER: Kleijnen S 

PROVIDER: S-EPMC5548837 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature